Studying Pathways of Resistance in KRAS-driven Cancers

Save

Report Abuse

Description

Up to 250 patients from anywhere in the United States can remotely consent and participate to have plasma drawn locally and submitted to Foundation Medicine, Inc. (FMI), for the FoundationOne® Liquid Biopsy Assay. Patients who have had resistance mechanisms determined through other assays can also consent to share these data. The Investigator(s) will compare mechanisms of acquired resistance across drugs (e.g. sotorasib vs adagrasib) and between tumor types (e.g. NSCLC vs CRC) to determine if different resistance mutations arise in these settings.

Targeted Conditions

Study Overview

Start Date
September 8, 2022
Completion Date
June 1, 2026
Enrollment
500
Date Posted
March 9, 2022
Accepts Healthy Volunteers?
No
Gender
All

Locations

Full Address
Dana-Farber Cancer Institute
Boston, Massachusetts 02215, United States

Eligibility

Study Population
Adult subjects with a diagnosis of acquired resistance to KRAS inhibitors
Minimum Age (years)
18
Eligibility Criteria
Inclusion Criteria:

Cohort 1A- Liquid Biopsy

Participants older than 18 years old at the time of consent or age of majority for residential state.
Demonstration of having advanced KRAS G12C positive cancer.
Systemic progression (not CNS only progression) within the past 30 days, having previously been treated with a therapeutic, targeting the specific KRAS mutation.
Patient must not have started a new line of therapy before signing the informed consent form.
Willingness to provide a blood specimen prior to the initiation of a new line of treatment.
Willingness to provide clinical and medical information to the study team as required.
Ability to read, write and communicate in English.
Ability to sign a web-based informed consent form.

Cohort 1B- Data Sharing

Participants older than 18 years old at the time of consent or age of majority for residential state.
Demonstration of having advanced KRAS G12C positive cancer.
Systemic progression (not CNS only progression) after being treated with a therapeutic targeting the specific KRAS mutation.
Patient must have prior tumor genotyping available (tissue or plasma) after progression on therapeutic targeting the specific KRAS mutation.
Willingness to provide clinical and medical information to the study team as required.
Ability to read, write and communicate in English.
Ability of the participant or legally authorized representative (LAR) to sign a web-based informed consent form.

Exclusion Criteria:

Participants who are unable to comply with the study procedures.
Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements.
Participants who have previously enrolled to the study.

Study Contact Info

Study Contact Name
Mark Awad, MD, PhD
Study Contact Email
Study Contact Phone

Contact Listings Owner Form

Studying Pathways of Resistance in KRAS-driven Cancers 0 reviews

Write Your Review

There are no reviews yet.

Write Your Review

Your email address will not be published. Required fields are marked *

Other Details

FDA Regulated Drug?
No
FDA Regulated Device?
No
Detailed Description
A hypothesis is that a remote participation plasma NGS study will characterize resistance mechanisms arising in KRAS-mutant cancers among individuals experiencing disease progression while on a KRAS-targeting therapy, and that subsequent therapies may be further personalized based on the results of plasma NGS testing.

After a web-based remote consent is obtained, subjects will be sent blood collection kits with the necessary materials for local draws and those specimens will be sent to the Dana-Farber Cancer Institute (DFCI), and rerouted to the central laboratory (Foundation Medicine, Inc.) for plasma NGS and to the ALCMI for storage. Plasma NGS results will be returned to the participant's treating physician, and the study team, aiming to be returned within approximately 2 weeks. In addition, subsequent treatments and clinical outcomes will be prospectively monitored. A correlation between the resistance mechanisms and clinical outcomes will be analyzed.

Patients with KRAS G12C mutant cancers will be enrolled in two cohorts.

Cohort 1A will enroll patients who are currently progressing on a KRAS G12C inhibitor and plasma for ctDNA analysis will be collected from these patients remotely.
Cohort 1B will enroll patients who have already had a sequencing assay performed to determine the resistance mechanism to a KRAS G12C inhibitor. These patients will be invited to share their data and medical history with the study team. Plasma for ctDNA analysis will be optional for this cohort.
NCTid (if applicable)
NCT05272423